Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
4 search results for:

Gemtuzumab ozogamicin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 07-09-2017 | Acute myeloid leukemia | News | Article

    Gemtuzumab ozogamicin accepted for CD33-positive AML
    approvalsWatch

    medwireNews : The US FDA has approved the use of gemtuzumab ozogamicin for several groups of patients with CD33-positive acute myeloid leukemia (AML).

  2. 20-11-2018 | FDA | News | Article
    approvalsWatch

    First-line peripheral T-cell lymphoma, AML drug use announced

    . --- NICE has published guidance recommending the use of gemtuzumab oxogamicin for patients aged 15 years or older with untreated CD33-positive AML.

  3. 15-11-2016 | Acute leukemia | Book chapter | Article

    Therapeutic management of acute promyelocytic leukemia

    However, for patients with molecular persistence who are not candidates for allogeneic HSCT, therapy with ATO or gemtuzumab ozogamicin may be considered.

    Author:
    Karsten Spiekermann
  4. 01-12-2015 | Hematologic cancers | Article

    Molecular therapy for acute myeloid leukaemia

    Further complicating investigation of this combination, gemtuzumab ozogamicin was voluntarily withdrawn by Pfizer in 2010, at the request of the FDA, owing to concerns regarding an initial lack of clinical benefit and liver toxicity 132 .

    Author:
    Catherine C. Coombs, Martin S. Tallman, Ross L. Levine
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.